-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
REVIEW: cumulative total investment of $ 479 million, Roche further increase its investment in the Suzhou Industrial Park Roche DiagnosticsAsia-Pacific R & D center and production base Recently, Roche announced that it will further increase investment it is located in the Suzhou industrial Park Roche diagnostics Asia-Pacific R & D center and production base, plans to increase total investment of 180 million US dollars, the cumulative total investment of $ 479 million, the capital increase will further deepen the strategic layout of Roche diagnostics in China, but also confirms once again the Roche diagnostics root in China, dedicated to the Chinese medical industry co-development for the benefit of long-term commitment to China and the Asia-Pacific patientsnew investment will be used for in vitro diagnostic reagents production and construction of various product lines and transfer projects including the organization of diagnostic reagents and staining platforms, including professional diagnostic reagentsAs the world leader in in vitro diagnostics, Roche Diagnostics is committed to providing advanced diagnostic solutions for the global patients, hospitals and laboratoriesDuring the fight against the global epidemic COVID-19's, Roche Diagnostics rapid response, research and development and to provide cobasSARS-CoV-2 nucleic acid qualitative detection [1] and Elecsys®Anti-SARS-CoV-2 antibody detection [2]Future, Roche Diagnostics Asia-Pacific R & D center and production base is also expected to play an important role in the global fight against the epidemic COVID-19, the production in China and other Asia-Pacific countries and supply detection productsChina is one of the Roche Group's global strategic focus, Roche Diagnostics has always been practicing a long-term commitment to the Chinese market and support the development of China's medical industry, bringing innovation to Chinese patients, accurate detection products, "Chinese health "the contribute to the buildingThe new investment will further boost Roche Diagnostics deepen the strategic layout in China, to enhance the ability to respond to market Roche Diagnostics, bringing the wider areas of China and the Asia-Pacific's high quality testing productsFuture, Roche Diagnostics will continue to explore the possibility of landing more projects in China, and work together parties to actively participate in the construction of medical innovation projects, with a view to more cutting-edge in vitro diagnostic solutions into China, for the benefit of Chinese patientsEditor: Meng MengRelated Tags:National, Roche, Chinese market
0
0